As you know I follow the science and it is obviously the main attraction. Just so happens RXI has on of the best CEO's in the business, IMHO. GLTA
Few falling off perhaps due to impatience and lower pps. RXI fundamentally stronger. Hard to justify lack of buying interest other than the time required to complete p2 and a lack of news.
But those two issues do not concern me, as Dr. C. isn't one to throw out PR very often, as you all know. The complete picture keeps my sentiment very bullish on the company.
He is results driven. Will keep my $ on him. It's why I'm here in the first place........GLTA
why does he keep trying to discredit RXI with half truths and scare tactics? I'll tell you why. Because his bosses are trying to buy shares on the cheap.
Why else would a person who does not like a company post on its message board 10 times per day?
Save your energy avi, everybody knows what you are doing and why you are here...............
Enough cash yes, but must never overlook the fact that a company cannot simply use up all cash and then go scrambling for more.
A cushion of at least one year's estimated burn must always be on hand. RXI is expanding and the burn rate will increase. Although I see no immediate need to raise $ especially with the equity line on hand from LPC, at some point down the road more funding needed. Perhaps partnerships will eliminate that need?
In any case, we are in very good hands. Dr. C. is a perfectly capable CFO, imho
Perhaps sentiment has been compromised with the fallen share price recently, but I see no fundamental reasons for it. If anything it has added to the attraction of new investment, IMHO.
Avi, your just a dope stock basher. but a dope firstly.................................GLTA
Courtesy of a poster from another site. taken from hFierce Bioteck" quote:
Dr. Phillip Frost has an enviable track record in the building and selling of bio businesses. An early success came in 1986 when, 14 years after taking over then-nearly-bankrupt Key Pharmaceuticals with Michael Jaharis, he sold the company to Schering-Plough. In his role as chairman, Frost helped build Key into a consistently profitable company with sales north of $150 million a year. Frost is thought to have earned around $150 million from selling his stake.
The sale gave Frost the funds to found what was to become the company that defined him as a builder of biopharma businesses, Ivax. Founded in 1987, Ivax made a series of acquisitions in its early years and became a major player in the sale of generic pharmaceuticals. Ivax was ahead of the curve on the rise of emerging markets and built strong positions in Latin America, Central and Eastern Europe and the United Kingdom. This robust global footprint attracted the attention of buyers, and in 2006 Israeli generics giant Teva ($TEVA) bought Ivax for $7.4 billion. Again, Frost took home a sizable return on his initial investment.
While building Ivax from his position as chairman, Frost found the time to found North American Vaccine, by combining the assets of two existing companies, and then sell the firm to Baxter ($BAX). Yet again, Frost made a tidy profit from the $390 million in cash, stock and debt Baxter coughed up for the vaccinemaker. A more recent success story is Protalix Biotherapeutics: Frost was among the first investors in the company, but largely cashed out in 2011. Now, the rare disease model pursued by Protalix has seen it partner with Pfizer ($PFE) and generate talk of a $1 billion takeover.
It is possible Frost could have increased returns on Protalix by holding onto his shares for a few more years, but even so he has grown his net worth to $2.6 billion, according to Forbes. These repeated successes mean that now when Frost backs a company people take notice. And Frost gives them plenty of firms to track. The biggest play is Opko Health, which, in a move mirroring the formation of other Frost companies, was created in a roll-up of several firms.
Dr. Cauwenbergh is neither here for the salary not the exercise. Note the credentials of his entire staff along with the close affiliation with Dr. Frost, et. al.
The recent early success with the eye experiments and the work on fibrosis in other than skin scarring are telling that even at this early stage with limited staff, his intentions are to expand in all the directions that his well patented science will both allow and promote.
Aside from the very discouraging pps at the moment, I am confident that he is following his "well conceived plan", and that the stock price and its recent fluctuation is of little concern to him short term.
Just my thought this afternoon. I like it. GLTA
What's up with that avi? Hmm? Too funny. GLTA
Oh my, ever wonder why avimoron is si interested in a loser stock? Too funny avi, you really have us all fooled.....................
I post factual information along with my opinions based on those facts. All truthful..
You just post #$%$ avi. you're a joke ......................
Save your breath sabaid, avi is a paid stock basher, paid to discredit the merits of RXI. He will never give reasons for the constant negativity, because he has none............
109 Has the Potential to T
reat a Wide Range of Indications in Various Therapeutic
Areas, Representing an
In addition to skin, CTGF plays a
role in other fibrotic diseases in ophthalmology, lungs, liver, and surgical/abdominal adhesions.
tegories are significant and represent an estimated market opportunity of greater than $10B.
For example, Lucentis was developed by Roche (SIX: RO) to treat wet macular degeneration and
diabetic macular edema, which RXI
109 could potentially treat. In 2010
, Lucentis brought in sales of
$2.9B. We believe that there could be several partnering opportunities for RXi to apply the
Company’s RNAi technology in these therapeutic areas over the next couple of years.
Article proving proof of concept. No doubt on this end that Cauwenbergh is following his quote; "Well conceived plan" Worth a re-read....................GLTA
C'mon avimoron, tell the board the real reasons why you post here so often, c'mon avi tell them.....